PE20000544A1 - Forma de dosificacion de nefazodona - Google Patents
Forma de dosificacion de nefazodonaInfo
- Publication number
- PE20000544A1 PE20000544A1 PE1999000481A PE00048199A PE20000544A1 PE 20000544 A1 PE20000544 A1 PE 20000544A1 PE 1999000481 A PE1999000481 A PE 1999000481A PE 00048199 A PE00048199 A PE 00048199A PE 20000544 A1 PE20000544 A1 PE 20000544A1
- Authority
- PE
- Peru
- Prior art keywords
- nefazodone
- micropells
- cps
- polymer
- hours
- Prior art date
Links
- 229960001800 nefazodone Drugs 0.000 title abstract 5
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 title abstract 5
- 239000002552 dosage form Substances 0.000 title abstract 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 4
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 abstract 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 2
- 235000019359 magnesium stearate Nutrition 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 2
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229920000642 polymer Polymers 0.000 abstract 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
- 239000000661 sodium alginate Substances 0.000 abstract 2
- 235000010413 sodium alginate Nutrition 0.000 abstract 2
- 229940005550 sodium alginate Drugs 0.000 abstract 2
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 abstract 1
- 102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 abstract 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000008119 colloidal silica Substances 0.000 abstract 1
- 239000003086 colorant Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 229960002441 nefazodone hydrochloride Drugs 0.000 abstract 1
- DYCKFEBIOUQECE-UHFFFAOYSA-N nefazodone hydrochloride Chemical compound [H+].[Cl-].O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 DYCKFEBIOUQECE-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
SE REFIERE A UNA FORMULACION FARMACEUTICA DE LIBERACION CONTROLADA/PROLONGADA DE NEFAZODONA Y QUE SE CARACTERIZA PORQUE LA LIBERACION DEL FARMACO SE DA DE LAS 4 A 16 HORAS, CON NIVELES TERAPEUTICOS PROLONGADOS HASTA POR 24 HORAS, CANTIDADES REDUCIDAS DE METABOLITOS DE NEFAZODONA TAL COMO m-CLOROFENILPIPERAZINA, NO ES INCOMPATIBLE CON EL ALIMENTO; TRATANDOSE DE UNA FORMA DE DOSIFICACION MODULADA POR EL pH, CON UNA VISCOSIDAD DE 3 cps A 100 cps; COMPRENDE DE 33% A 45.5% DE CLORHIDRATO DE NEFAZODONA, DE 16% A 33% DE UN POLIMERO DE GELIFICACION NO IONICO (HIDROXIPROPILMETILCELULOSA), DE 10% A 21% DE UN POLIMERO DE GELIFICACION IONICO (ALGINATO DE SODIO), DE 16% A 22% DE UN AGENTE HIDROFILICO INSOLUBLE (CELULOSA MICROCRISTALINA). LOS EXCIPIENTES DE LA FORMULACION PUEDEN SER COLORANTES, SILICE COLOIDAL, ESTEARATO DE MAGNESIO. LA NEFAZODONA ESTA INCRUSTADA EN UNA MATRIZ, FORMADA EN MICROPELLAS o FORMADA EN MICROPELLAS RECUBIERTAS. UNA COMPOSICION PREFERIDA CONTIENE DE 40%-45% DE CLORHIDRATO DE NEFAZODONA, DE 16% A 20% DE HIDROXIPROPILMETILCELULOSA, DE 19%-22% DE ALGINATO DE SODIO, DE 19%-22% DE CELULOSA MICROCRISTALINA, DE 1%-15% DE ESTEARATO DE MAGNESIO. LA NEFAZODONA ES UTIL COMO BLOQUEADOR DEL RECEPTOR 5HT DE SEROTONINA ACTUANDO COMO ANTIDEPRESOR
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8821198P | 1998-06-05 | 1998-06-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20000544A1 true PE20000544A1 (es) | 2000-06-29 |
Family
ID=22210038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1999000481A PE20000544A1 (es) | 1998-06-05 | 1999-06-04 | Forma de dosificacion de nefazodona |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US6143325A (es) |
| EP (1) | EP0966966A3 (es) |
| JP (1) | JP2000007567A (es) |
| KR (1) | KR20000005930A (es) |
| CN (1) | CN1238181A (es) |
| AR (1) | AR018862A1 (es) |
| AU (1) | AU3319999A (es) |
| BR (1) | BR9901782A (es) |
| CA (1) | CA2273546A1 (es) |
| CO (1) | CO5060477A1 (es) |
| HU (1) | HUP9901830A2 (es) |
| ID (1) | ID23458A (es) |
| IL (1) | IL130022A0 (es) |
| NO (1) | NO992692L (es) |
| NZ (1) | NZ336001A (es) |
| PE (1) | PE20000544A1 (es) |
| PL (1) | PL333524A1 (es) |
| SG (1) | SG77244A1 (es) |
| UY (1) | UY25544A1 (es) |
| ZA (1) | ZA993345B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6143325A (en) * | 1998-06-05 | 2000-11-07 | Bristol-Myers Squibb Company | Nefazodone dosage form |
| EP1428535A1 (en) * | 1998-11-02 | 2004-06-16 | ALZA Corporation | Controlled delivery of antidepressants |
| US6706282B1 (en) | 1998-11-02 | 2004-03-16 | Evangeline Cruz | Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones |
| KR100734193B1 (ko) * | 1998-11-02 | 2007-07-02 | 알자 코포레이션 | 항우울제의 제어된 전달 |
| AU2002306616A1 (en) * | 2001-03-02 | 2002-09-19 | Sepracor Inc. | Composition containing a nefazonoid such as nefazodone and a serotonin-inhibitor such as fluoxetine |
| US8329216B2 (en) | 2001-07-06 | 2012-12-11 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
| US7276250B2 (en) | 2001-07-06 | 2007-10-02 | Penwest Pharmaceuticals Company | Sustained release formulations of oxymorphone |
| CA2452872A1 (en) | 2001-07-06 | 2003-01-16 | Endo Pharmaceuticals, Inc. | Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic |
| US20040220240A1 (en) * | 2001-11-28 | 2004-11-04 | Pellegrini Cara A. | Method of increasing the extent of absorption of tizanidine |
| US6455557B1 (en) | 2001-11-28 | 2002-09-24 | Elan Pharmaceuticals, Inc. | Method of reducing somnolence in patients treated with tizanidine |
| US6407128B1 (en) | 2001-12-03 | 2002-06-18 | Elan Pharmaceuticals, Inc. | Method for increasing the bioavailability of metaxalone |
| US7714006B1 (en) | 2001-12-03 | 2010-05-11 | King Pharmaceuticals Research & Development, Inc. | Methods of modifying the bioavailability of metaxalone |
| DE50312523D1 (de) * | 2002-05-24 | 2010-04-29 | Carl-Fr Coester | Pharmazeutische wirkstoffkombination sowie deren verwendung |
| TWI319713B (en) | 2002-10-25 | 2010-01-21 | Sustained-release tramadol formulations with 24-hour efficacy | |
| US8487002B2 (en) | 2002-10-25 | 2013-07-16 | Paladin Labs Inc. | Controlled-release compositions |
| GB0306604D0 (en) * | 2003-03-21 | 2003-04-30 | Curidium Ltd | Second medical use |
| AP1899A (en) * | 2003-08-08 | 2008-10-10 | Biovail Lab Int Srl | Modified-release tablet of bupropion hydrochloride |
| US7893261B2 (en) | 2004-03-26 | 2011-02-22 | Baylor University | Serotonin reuptake inhibitors |
| BRPI0615860B8 (pt) * | 2005-09-09 | 2021-05-25 | Labopharm Barbados Ltd | composição farmacêutica de liberação prolongada monolítica sólida |
| US20080287508A1 (en) * | 2007-05-18 | 2008-11-20 | Intermune, Inc. | Altering pharmacokinetics of pirfenidone therapy |
| US20100159001A1 (en) * | 2008-12-19 | 2010-06-24 | Cardinal John R | Extended-Release Pharmaceutical Formulations |
| US20100160363A1 (en) * | 2008-12-19 | 2010-06-24 | Aaipharma Services Corp. | Extended-release pharmaceutical formulations |
| WO2012072665A1 (en) | 2010-11-30 | 2012-06-07 | Pharmaneuroboost N.V. | Compositions comprising pipamperone and serotonin antagonist reuptake inhibitors |
| JP2011140510A (ja) * | 2011-03-17 | 2011-07-21 | Biovail Lab Inc | 塩酸ブプロピオンの放出調節錠剤 |
| ES2821528T3 (es) | 2012-11-14 | 2021-04-26 | Grace W R & Co | Composiciones que contienen un material biológicamente activo y un óxido inorgánico no ordenado |
| JP6184903B2 (ja) * | 2014-06-04 | 2017-08-23 | ヴァレアント インターナショナル バミューダＶａｌｅａｎｔ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｂｅｒｍｕｄａ | 塩酸ブプロピオン放出調節錠剤 |
| JP6078514B2 (ja) * | 2014-10-30 | 2017-02-08 | コリア ユナイテッド ファーム，インク | 溶出率向上と副作用発現が最小化されたシルロスタゾール徐放錠 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4792452A (en) * | 1987-07-28 | 1988-12-20 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
| US4983398A (en) * | 1987-12-21 | 1991-01-08 | Forest Laboratories, Inc. | Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates |
| US5431922A (en) * | 1991-03-05 | 1995-07-11 | Bristol-Myers Squibb Company | Method for administration of buspirone |
| US5169638A (en) * | 1991-10-23 | 1992-12-08 | E. R. Squibb & Sons, Inc. | Buoyant controlled release powder formulation |
| US5536507A (en) * | 1994-06-24 | 1996-07-16 | Bristol-Myers Squibb Company | Colonic drug delivery system |
| ES2196180T3 (es) * | 1995-09-29 | 2003-12-16 | Lam Pharmaceutical Corp | Sistema de suministro de liberacion sostenida y analgesicos de narcoticos y antagonistas de accion prolongada. |
| WO1997047285A1 (en) * | 1996-06-10 | 1997-12-18 | Depomed, Inc. | Gastric-retentive oral controlled drug delivery system with enhanced retention properties |
| US6143325A (en) * | 1998-06-05 | 2000-11-07 | Bristol-Myers Squibb Company | Nefazodone dosage form |
-
1999
- 1999-04-26 US US09/299,959 patent/US6143325A/en not_active Expired - Lifetime
- 1999-05-14 ZA ZA9903345A patent/ZA993345B/xx unknown
- 1999-05-19 IL IL13002299A patent/IL130022A0/xx unknown
- 1999-05-28 NZ NZ336001A patent/NZ336001A/xx unknown
- 1999-06-01 SG SG1999002831A patent/SG77244A1/en unknown
- 1999-06-02 PL PL99333524A patent/PL333524A1/xx not_active Application Discontinuation
- 1999-06-03 CA CA002273546A patent/CA2273546A1/en not_active Abandoned
- 1999-06-03 HU HU9901830A patent/HUP9901830A2/hu unknown
- 1999-06-03 AR ARP990102618A patent/AR018862A1/es unknown
- 1999-06-03 NO NO992692A patent/NO992692L/no not_active Application Discontinuation
- 1999-06-04 PE PE1999000481A patent/PE20000544A1/es not_active Application Discontinuation
- 1999-06-04 EP EP99110777A patent/EP0966966A3/en not_active Withdrawn
- 1999-06-04 KR KR1019990020676A patent/KR20000005930A/ko not_active Application Discontinuation
- 1999-06-04 JP JP11157499A patent/JP2000007567A/ja active Pending
- 1999-06-04 ID IDP990521D patent/ID23458A/id unknown
- 1999-06-04 AU AU33199/99A patent/AU3319999A/en not_active Abandoned
- 1999-06-04 BR BR9901782-2A patent/BR9901782A/pt not_active IP Right Cessation
- 1999-06-04 UY UY25544A patent/UY25544A1/es not_active Application Discontinuation
- 1999-06-04 CO CO99035356A patent/CO5060477A1/es unknown
- 1999-06-07 CN CN99108308A patent/CN1238181A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2273546A1 (en) | 1999-10-10 |
| BR9901782A (pt) | 2000-05-09 |
| UY25544A1 (es) | 2001-08-27 |
| ID23458A (id) | 2000-04-27 |
| CN1238181A (zh) | 1999-12-15 |
| IL130022A0 (en) | 2000-02-29 |
| SG77244A1 (en) | 2000-12-19 |
| AR018862A1 (es) | 2001-12-12 |
| US6143325A (en) | 2000-11-07 |
| KR20000005930A (ko) | 2000-01-25 |
| HUP9901830A2 (hu) | 2001-06-28 |
| EP0966966A2 (en) | 1999-12-29 |
| AU3319999A (en) | 1999-12-16 |
| NZ336001A (en) | 2000-09-29 |
| PL333524A1 (en) | 1999-12-06 |
| ZA993345B (en) | 2000-08-22 |
| HU9901830D0 (en) | 1999-07-28 |
| EP0966966A3 (en) | 2000-02-09 |
| JP2000007567A (ja) | 2000-01-11 |
| NO992692L (no) | 1999-12-06 |
| NO992692D0 (no) | 1999-06-03 |
| CO5060477A1 (es) | 2001-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20000544A1 (es) | Forma de dosificacion de nefazodona | |
| AR001405A1 (es) | Formulación oral de 2-metil-tieno-beno-diacepina. | |
| KR100858848B1 (ko) | 메트포르민 서방정 | |
| EE05022B1 (et) | Eelthelatineeritud tärklise kasutamine hüdrofiilses kontrollitud vabanemisega preparaadis ja hüdrofiilne kontrollitud vabanemisega preparaat | |
| AR022672A1 (es) | Una composicion farmaceutica en forma de tabletas o capsulas que constituyen un metodo de administracion oral de una droga | |
| JPH09143073A (ja) | 持続性ニフエジピン製剤 | |
| CA2464578A1 (en) | Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient | |
| Rathore et al. | Preparation and characterization of timolol maleate ocular films | |
| KR960010007A (ko) | 게피론 용량형 | |
| DE60038536D1 (de) | Matrixsystem mit verzögerter freisetzung für hochlösliche wirkstoffe | |
| US6994871B2 (en) | Once a day antihistamine and decongestant formulation | |
| CZ287844B6 (en) | Oral preparation with prolonged release | |
| WO2005107716A1 (en) | Controlled release paroxetine-containing tablets based on a core and a coating | |
| CN108785263B (zh) | 普拉克索或其药用盐的固体药物组合物及其制备方法 | |
| AU2002311622A1 (en) | Long acting compositions comprising zidovudine and lamivudine | |
| CN100563657C (zh) | 依诺沙星眼用缓释凝胶剂及其制备方法 | |
| RU2442570C1 (ru) | Таблетка с замедленным высвобождением, содержащая гидрохлорид альфузозина | |
| US20050095286A1 (en) | Extended release compositions | |
| RU99111964A (ru) | Форма дозировки нефазодона | |
| JPWO2020201515A5 (es) | ||
| RS52094B (en) | KIDNEY ERODIBLE MATRIX SYSTEM WITH CONTROLLED ACTIVE SUBSTANCE RELEASE | |
| ECSP992975A (es) | Forma de dosificacion de nefazodona | |
| ECSP961693A (es) | Formulacion oral de 2- metil-tieno-benzodiaceptina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |